CC-671
Based on 1 publication(s) in Google Scholar
CC-671 is a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor with IC50s of 0.005 and 0.006 μM for TTK and CLK2, respectively.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.06%
- No. CAS: 1618658-88-0
- Fòrmula: C28H28N6O4
- Peso molecular:512.56
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) CC-671
More
Actividad biológica
|
CLK2 0.006 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BT-474 | IC50 |
6.97 μM
Compound: 23; CC-671
|
Cytotoxicity against human BT474 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo assay
Cytotoxicity against human BT474 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo assay
|
[PMID: 28991472] |
| CAL-51 | IC50 |
0.06 μM
Compound: 23; CC-671
|
Cytotoxicity against human CAL51 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo assay
Cytotoxicity against human CAL51 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo assay
|
[PMID: 28991472] |
| CAL-51 | IC50 |
0.028 μM
Compound: 1; CC-671
|
Antiproliferative activity against human CAL51 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo reagent-based luminescent assay
Antiproliferative activity against human CAL51 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo reagent-based luminescent assay
|
[PMID: 30998356] |
| CAL-51 | IC50 |
15 nM
Compound: CC-671
|
Antiproliferative activity against human CAL-51 cells assessed as inhibition of cell proliferation measured after 96 hrs by Cell Titer Glo assay
Antiproliferative activity against human CAL-51 cells assessed as inhibition of cell proliferation measured after 96 hrs by Cell Titer Glo assay
|
[PMID: 35872347] |
| CAL-51 | IC50 |
0.06 μM
Compound: 5f; CC-671
|
Antiproliferative activity against human CAL-51 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human CAL-51 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 38795520] |
CC-671 (compound 23) is a dual TTK protein kinase/CDC2-like kinase (CLK2) inhibitor with IC50s of 0.005 and 0.006 μM for TTK and CLK2, respectively. HCT-116 cell lysates treated with CC-671 at 3 μM for 1 h demonstrates that only four kinases show cellular binding of 75% or more including CLK2, CAMKK2, PIP4K22, and JNK[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 1618658-88-0
-
Appearance Solid
-
Peso molecular 512.56
-
Fòrmula C28H28N6O4
-
Color Off-white to light green
-
SMILES
O=C(NC)C1=CC=C(NC2=NC(NC=C3C4=CC(OC(C)=N5)=C5C=C4)=C3C(OC6CCCC6)=N2)C(OC)=C1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
2022 Oct 10;40(10):1128-1144.e8. PMID: 36150391
Solvente y solubilidad
DMSO : ≥ 60 mg/mL (117.06 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.06 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (4.06 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocolo
The kinase selectivity profile of CC-671 (compound 23) is assessed. The screen is conducted with the concentration of CC-671 held constant at 3 μM. The TTK binding affinity is measured using the kinase binding assays. The kinase binding assays are based on the binding and displacement of a proprietary, Alexa Fluor 647-labeled, ATP-competitive kinase inhibitor scaffold[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Female SCID mice are inoculated subcutaneously with 5×106 Cal-51 cells. Mice with tumors of approximately 125 mm3 are randomized and treated intravenously at various doses and schedules of CC-671 (compound 23) (n=8 to10/group). Tumors are measured twice a week for the duration of the study. The long and short axes of each tumor are measured using a digital caliper in millimeters and the tumor volumes are calculated[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureza y Documentación
-
Ficha de datos (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9510 mL | 9.7550 mL | 19.5099 mL | 48.7748 mL |
| 5 mM | 0.3902 mL | 1.9510 mL | 3.9020 mL | 9.7550 mL | |
| 10 mM | 0.1951 mL | 0.9755 mL | 1.9510 mL | 4.8775 mL | |
| 15 mM | 0.1301 mL | 0.6503 mL | 1.3007 mL | 3.2517 mL | |
| 20 mM | 0.0975 mL | 0.4877 mL | 0.9755 mL | 2.4387 mL | |
| 25 mM | 0.0780 mL | 0.3902 mL | 0.7804 mL | 1.9510 mL | |
| 30 mM | 0.0650 mL | 0.3252 mL | 0.6503 mL | 1.6258 mL | |
| 40 mM | 0.0488 mL | 0.2439 mL | 0.4877 mL | 1.2194 mL | |
| 50 mM | 0.0390 mL | 0.1951 mL | 0.3902 mL | 0.9755 mL | |
| 60 mM | 0.0325 mL | 0.1626 mL | 0.3252 mL | 0.8129 mL | |
| 80 mM | 0.0244 mL | 0.1219 mL | 0.2439 mL | 0.6097 mL | |
| 100 mM | 0.0195 mL | 0.0975 mL | 0.1951 mL | 0.4877 mL |
CC-671 Related Classifications
HY-108709 Related Classifications
Powered by Bioz